Acrivon Therapeutics, Inc. (ACRV): Total Liabilities
$17.20M
As of 2025-12-31
$12.43M
As of 2026-06-30
+17.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.20M | -13.1% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $19.80M | +16.0% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $17.07M | +58.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $10.75M | +36.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $7.88M | n/a | 2023-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $17.20M | -13.1% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $53.41M | +25.5% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $69.14M | +0.8% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $11.64M | -0.5% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $93.97M | -25.4% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $39.41M | -8.1% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $115.12M | -71.1% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $2.89M | -45.0% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
Compare ACRV, CTXR, SLN, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗